Meropenem
- Generic Name
- Meropenem
- Brand Names
- Vabomere
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O5S
- CAS Number
- 96036-03-2
- Unique Ingredient Identifier
- YOP6PX0BAO
- Background
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
...
- Indication
For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, vi...
- Associated Conditions
- Bacterial Infections, Complicated Intra-Abdominal Infections (cIAIs), Meningitis, Bacterial, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin infection bacterial
- Associated Therapies
- -
RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.
- Conditions
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 391
- Registration Number
- NCT02176122
- Locations
- 🇮🇹
Catholic University Rome, Rome, Italy
🇹🇷İstanbul Medipol Üniversitesi Medipol Mega Hastaneler Kompleksi (Medipol Mega Hospitals Complex), Istanbul, Turkey
🇦🇺Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
- Conditions
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2020-05-05
- Target Recruit Count
- 726
- Registration Number
- NCT02070757
Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 90
- Registration Number
- NCT02047773
- Locations
- 🇬🇧
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Erzhen Chen
- Target Recruit Count
- 60
- Registration Number
- NCT01992198
- Locations
- 🇨🇳
Depatrment of EICU,Ruijin Hospital, Shanghai, Shanghai, China
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
- Conditions
- Interventions
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Achaogen, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT01970371
Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem
- Conditions
- Interventions
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Mical Paul
- Target Recruit Count
- 406
- Registration Number
- NCT01732250
- Locations
- 🇮🇱
Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
🇮🇱Rambam Health Care Center, Haifa, Israel
🇬🇷Laikon Hosptial, Athens, Greece
Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
- Conditions
- Interventions
- First Posted Date
- 2012-11-14
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 486
- Registration Number
- NCT01726023
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- PENTA Foundation
- Target Recruit Count
- 51
- Registration Number
- NCT01554124
- Locations
- 🇬🇧
HEATH, Paul, London, Cranmer Terrace, United Kingdom
Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis
- Conditions
- Interventions
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- PENTA Foundation
- Target Recruit Count
- 272
- Registration Number
- NCT01551394
- Locations
- 🇮🇹
Ursula TRAFOJER, Padova, Italy
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 493
- Registration Number
- NCT01499290
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.